Antidepressants increase risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. Nefazodone not FDA approved for use in children. May worsen psychosis in some patients or precipitate shift to mania or hypomania in bipolar disorder. Monotherapy in bipolar disorder should be avoided. Nefazodone not FDA approved for treatment of bipolar depression. May cause anticholinergic effects (blurred vision, constipation, urinary retention, xerostomia); use with caution in decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Degree of anticholinergic blockade produced by this agent is very low relative to other antidepressants. Cases of life-threatening hepatic failure reported. May cause orthostatic hypotension (risk low relative to other antidepressants). May cause sedation (degree of sedation low relative to other antidepressants). Rare reports of priapism occurred. Incidence of sexual dysfunction with nefazodone generally lower than with SSRIs. Use with caution in history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); risk of conduction abnormalities with this agent is very low relative to other antidepressants. Use with caution in renal impairment, or in risk of seizures, including patients with history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Effects may be potentiated when used with other sedative drugs. Use with caution in the elderly. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods. May increase risks associated with electroconvulsive therapy.